Interesting facts
Interesting Facts about the Compound
This fascinating compound, with its complex structure, is part of a class of molecules with significant biological implications. Here are some noteworthy aspects:
- Biological Relevance: This compound has been studied for its potential application in medicinal chemistry, particularly in the field of antiviral agents and nucleotide analogs.
- Efficient Delivery: The sugar-like tetrahydrofuran ring enhances solubility and absorption, making it an attractive candidate for drug delivery systems.
- Enzymatic Interaction: The presence of the phosphoryl group suggests that this compound may interact with kinases and phosphatases, which are critical in cellular signaling and metabolism.
- Analogs and Derivatives: Researchers often create various analogs of such compounds to explore modifications that could improve efficacy or reduce side effects in therapeutic applications.
- Potential for Research: Due to its unique structure, this compound serves as a fantastic template for developing new chemical entities for further research.
In the words of a renowned chemist, “The beauty of chemistry lies in the infinite possibilities of molecular architecture and its ability to influence life itself.” This compound perfectly embodies that sentiment, making it a topic of great interest among chemists and biologists alike.
As investigations continue, this compound may unlock new pathways in drug development and therapeutic strategies, proving that even complex molecules can lead to groundbreaking advancements in science.
Synonyms
nadide
53-84-9
coenzyme I
NAD+
beta-NAD
beta-nicotinamide adenine dinucleotide
Codehydrogenase I
diphosphopyridine nucleotide
Codehydrase I
nicotinamide adenine dinucleotide
beta-Diphosphopyridine nucleotide
Cozymase I
beta-NAD+
COZYMASE
Enzopride
Nadidum
Nicotinamide-adenine dinucleotide
NAD
codehydrogenase
Nadida
CO-I
Nicotinamide dinucleotide
Pyridine, nucleotide diphosphate
Adenine-nicotinamide dinucleotide
Nicotineamide adenine dinucleotide
Nadidum [INN-Latin]
NAD zwitterion
Nadida [INN-Spanish]
CO-1
beta-DPN
.beta.-NAD
Nadide [USAN:INN:BAN:JAN]
EINECS 200-184-4
MFCD00036253
NSC 20272
BRN 3584133
0U46U6E8UK
NADIDE [USAN]
NADIDUM [HPUS]
NADIDE [INN]
NADIDE [JAN]
NADIDE [WHO-DD]
NADIDE [MART.]
NSC-20272
NAD(SUP +)
3-Carbamoyl-1-beta-D-ribofuranosylpyridinium hydroxide, 5'-ester with adenosine 5'-pyrophosphate, inner salt
DTXSID2045236
CHEBI:44215
Nicotinamide Adinine Dinucleotide
EC 200-184-4
5-26-16-00399 (Beilstein Handbook Reference)
Adenosine 5'-(trihydrogen diphosphate), P'-5'-ester with 3-(aminocarbonyl)-1-beta-D-ribofuranosylpyridinium hydroxide, inner salt
Nicotinamide adenine dinucleotide (NAD)
Nadidum (INN-Latin)
Coenzyme 1
Nadida (INN-Spanish)
NADIDE (MART.)
DPN-ox
64417-72-7
NAD Lithium salt
Endopride
1-((2R,3R,4S,5R)-5-((((((((2R,3S,4R,5R)-5-(6-Amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)oxy)oxidophosphoryl)oxy)methyl)-3,4-dihydroxytetrahydrofuran-2-yl)-3-carbamoylpyridin-1-ium
Adenosine 5'-(trihydrogen diphosphate), 5'-5'-ester with 3-(aminocarbonyl)-1-beta-D-ribofuranosylpyridinium, hydroxide, inner salt
Pyridinium, 3-carbamoyl-1-beta-D-ribofuranosyl-, hydroxide, 5'-ester with adenosine 5'-5'-(trihydrogen pyrophosphate), inner salt
DPN+
NAD+, Free Acid
beta-Nicotinamide adenine dinucleotide hydrate
Adenosine 5'-(trihydrogen diphosphate), P'-5'-ester with 3-(aminocarbonyl)-1-beta-D-ribofuranosylpyridinium, inner salt
3-CARBAMOYL-1-.BETA.-D-RIBOFURANOSYLPYRIDINIUM HYDROXIDE 5'->5'-ESTER WITH ADENOSINE 5'-(TRIHYDROGEN PYROPHOSPHATE) INNER SALT
3-CARBAMOYL-1-.BETA.-D-RIBOFURANOSYLPYRIDINIUM HYDROXIDE, 5'-ESTER WITH ADENOSINE 5'-PYROPHOSPHATE, INNER SALT
ADENOSINE 5'-(TRIHYDROGEN DIPHOSPHATE) P'->5'-ESTER WITH 3-(AMINOCARBONYL)-1-.BETA.-D-RIBOFURANOSYLPYRIDINIUM INNER SALT
ADENOSINE 5'-(TRIHYDROGEN DIPHOSPHATE), 5'->5'-ESTER WITH 3-(AMINOCARBONYL)-1-.BETA.-D-RIBOFURANOSYLPYRIDINIUM, HYDROXIDE, INNER SALT
Adenosine 5'-(trihydrogen diphosphate), P'->5'-ester with 3-(aminocarbonyl)-1-beta-D-ribofuranosylpyridinium, inner salt
Adenosine 5'-(trihydrogen diphosphate), P'.fwdarw.5'-ester with 3-(aminocarbonyl)-1-beta-D-ribofuranosylpyridinium, inner salt
Co I
nadid
UNII-0U46U6E8UK
b-Nicotinamide adenine dinucleotide
NADLithiumsalt
NSC20272
beta-Diphosphopyridinenucleotide
NAD trihydrate
betaNAD
betaNAD+
CAS-53-84-9
NCGC00016240-01
(((2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl)methoxy-oxidophosphoryl) ((2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl)methyl phosphate;hydron
[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl] [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate;hydron
Viatrexx-NAD Plus
NAD+ (Standard)
b-NAD, oxidised form
beta-NAD, oxidised form
((2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl)methyl (((2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl)methoxy-hydroxyphosphoryl) phosphate
[(2R,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl [[(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphate
[adenylate-32-P]-NAD
Adenosine 5'-(trihydrogen diphosphate), P'.fwdarw.5'-ester with 3-(aminocarbonyl)-1-.beta.-D-ribofuranosylpyridinium, inner salt
Carbonyl [14C] NAD+
NAD [MI]
NAD, Grade I, free acid
[adenylate-32-P]-NAD+
NAD, Grade II, free acid
SCHEMBL131544
SPECTRUM1500419
Pyridine nucleotide diphosphate
Adeninenicotinamide dinucleotide
betaDiphosphopyridine nucleotide
Nicotinamideadenine dinucleotide
GTPL2451
CHEMBL1234613
DTXCID0025236
HMS500J11
HY-B0445R
[14C] NAD+
[32P] NAD+
BDBM213227
GLXC-10877
HMS2091H06
HMS2097E04
HMS3714E04
Pharmakon1600-01500419
EX-A3535
HY-B0445
betaNicotinamide adenine dinucleotide
Tox21_110321
CCG-40114
MSK000609
NSC757121
s2518
bera-Nicotinamide adenine dinucleotide
AKOS015892319
beta-nicotinamide adenine din-ucleotide
DB14128
NN11969
NSC-757121
.beta.-Nicotinamide adenine dinucleotide
NCGC00178839-01
NCGC00178839-02
NCGC00178839-03
NCGC00178839-08
[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate
|A-DPN; |A-NAD; Coenzyme 1; Nadide
AC-37031
AS-14652
BP-58726
SBI-0051451.P003
AB00513910
D0919
NS00100300
-DPN;-NAD;-Nicotinamide Adenine Dinucleotide
?-NAD;Coenzyme 1;Diphosphopyridine nucleotide
beta-Nicotinamide adenine dinucleotide, reduced
NICOTINAMIDE ADENINE DINUCLEOTIDE [INCI]
AB00052048_03
beta-Nicotinamide adenine dinucleotide trihydrate
beta-Nicotinamide adenine dinucleotide hydrate, >=99%
Q12499775
|A-Nicotinamide adenine dinucleotide pound NAD pound(c)
F45C0D6C-DA87-47BE-9975-7A5DE9CCB985
beta-Nicotinamide adenine dinucleotide hydrate, >=95% (HPLC)
beta-Nicotinamide adenine dinucleotide, pkg of 10 mg (per vial)
beta-Nicotinamide adenine dinucleotide, pkg of 20 mg (per vial)
beta-Nicotinamide adenine dinucleotide, pkg of 50 mg (per vial)
beta-Nicotinamide adenine dinucleotide hydrate, >=98%, BioUltra, from yeast
beta-Nicotinamide adenine dinucleotide hydrate, Grade AA-1, >=95% (HPLC)
3-Carbamoyl-1-D-ribofuranosylpyridinium hydroxide 5'-ester with adenosine 5'-pyrophosphate
beta-Nicotinamide adenine dinucleotide hydrate, purified by column chromatography, >=99%
beta-Nicotinamide adenine dinucleotide hydrate, Vetec(TM) reagent grade, >=96.5%
[(3S,2R,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl {[(3S,2R,4R,5R)-5-(3-carbamoylpyridyl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxyphosphoryl) hydrogen phosphate
[(3S,2R,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl {[(3S,2R,4R,5R)-5-(3-carbamoylpyridyl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxyphosphoryl)hydrogen phosphate
[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methoxy-hydroxy-phosphoryl] [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methyl hydrogen phosphate
1-[(2R,3R,4S,5R)-5-{[({[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl phosphonato)oxy]methyl}-3,4-dihydroxyoxolan-2-yl]-3-carbamoyl-1-pyridin-1-ylium
200-184-4
3-CARBAMOYL-1-BETA-D-RIBOFURANOSYLPYRIDINIUM HYDROXIDE 5'->5'-ESTER WITH ADENOSINE 5'-(TRIHYDROGEN PYROPHOSPHATE) INNER SALT
3-Carbamoyl-1-Beta-D-Ribofuranosylpyridinium Hydroxide 5'-5'-Ester with Adenosine 5'-(Trihydrogen Pyrophosphate) Inner Salt
3-Carbamoyl-1-beta-D-ribofuranosylpyridinium hydroxide 5'-ester with adenosine 5'-pyrophosphate inner salt
3-Carbamoyl-1-beta-delta-ribofuranosylpyridinium hydroxide 5'-ester with adenosine 5'-pyrophosphate inner salt
3-Carbamoyl-1-delta-ribofuranosylpyridinium hydroxide 5'-ester with adenosine 5'-pyrophosphate
3Carbamoyl1betaDribofuranosylpyridinium hydroxide, 5'ester with adenosine 5'pyrophosphate, inner salt
Adenosine 5'(trihydrogen diphosphate), 5'5'ester with 3(aminocarbonyl)1betaDribofuranosylpyridinium, hydroxide, inner salt
Adenosine 5'(trihydrogen diphosphate), P'.fwdarw.5'ester with 3(aminocarbonyl)1betaDribofuranosylpyridinium, inner salt
Adenosine 5'(trihydrogen diphosphate), P'>5'ester with 3(aminocarbonyl)1betaDribofuranosylpyridinium, inner salt
Adenosine 5'(trihydrogen diphosphate), P'5'ester with 3(aminocarbonyl)1betaDribofuranosylpyridinium hydroxide, inner salt
Adenosine 5'(trihydrogen diphosphate), P'5'ester with 3(aminocarbonyl)1betaDribofuranosylpyridinium, inner salt
ADENOSINE 5'-(TRIHYDROGEN DIPHOSPHATE) P'->5'-ESTER WITH 3-(AMINOCARBONYL)-1-BETA-D-RIBOFURANOSYLPYRIDINIUM INNER SALT
ADENOSINE 5'-(TRIHYDROGEN DIPHOSPHATE), 5'->5'-ESTER WITH 3-(AMINOCARBONYL)-1-BETA-D-RIBOFURANOSYLPYRIDINIUM, HYDROXIDE, INNER SALT
Adenosine 5'-(trihydrogen diphosphate-P-32P), P'>5'-ester with 3-(aminocarbonyl)-1-beta-D-ribofuranosylpyridinium, inner salt (9CI)
beta-Nicotinamide adenine dinucleotide hydrate, >=96.5% (HPLC), >=96.5% (spectrophotometric assay), from yeast
beta-Nicotinamide adenine dinucleotide hydrate, cell culture tested, >=96.5% (HPLC), >=96.5% (spectrophotometric assay), from yeast
Pyridinium, 3-carbamoyl-1-b-D-ribofuranosyl-, hydroxide, 5'-5'-ester with adenosine 5'-(trihydrogen pyrophosphate), inner salt (8CI)
Pyridinium, 3carbamoyl1betaDribofuranosyl, hydroxide, 5'ester with adenosine 5'5'(trihydrogen pyrophosphate), inner salt
Solubility of [(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methoxy-hydroxy-phosphoryl] [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methyl phosphate
The solubility of complex organic compounds such as C21H27N7O14P2 often depends on various structural and environmental factors. This particular compound exhibits a notably intricate molecular architecture influenced by both hydrophilic and hydrophobic regions, which play a critical role in its solubility behavior.
Factors Influencing Solubility:
In general, compounds like this exhibit higher solubility in:
Overall, it is essential to consider both the individual characteristics of the compound and the target solvent system to predict solubility adequately. The dynamic interplay of forces at work in solvation often leads to unique solubility profiles that merit thorough investigation.